- NAD headline
- As low as $89
- Billing period
- Not established by the homepage card
- Renewal
- Recurring-service terms apply when a subscription is selected
A visible offer within a broader storefront
Velvet Rx's homepage separately lists NAD+ injection, sermorelin injection, several weight-management offers and a GHK-Cu face cream. The NAD+ card advertises an as-low-as price of $89. That establishes a published starting offer, but the card does not clearly identify its supply period, full initial charge or continuing renewal rate.
The wider site's celebrity and weight-loss presentation should not become evidence for the NAD+ product. We review the relevant injection on its own terms and have not enrolled, assessed a patient's results or verified a clinical advantage from a public endorsement. A provider can offer several products without every outcome or approval claim applying across the catalog.
What the $89 headline leaves unresolved
Ask whether $89 describes a first order, a monthly equivalent, a particular supply or a conditional promotion. The answer should include the amount charged today and the date and amount of any later payment. Without that billing basis, the figure cannot be compared fairly with an explicitly priced vial or one-time package from another provider.
The quote should also identify assessment, medication, supplies, delivery and follow-up. Velvet's general terms allow certain shipping, processing and partner charges, so a reader should confirm the applicable inclusions rather than assuming an advertised starting price covers every step. These questions are about the selected order, not a claim that an undisclosed fee will necessarily be charged.
The subscription terms are relevant
Velvet's terms describe recurring services that continue automatically unless canceled under the applicable conditions. They state that the payment interval is disclosed during checkout. The document also names Rocket Health Inc and explains that charges may appear under that name or an identified partner, a useful detail to reconcile with the final order confirmation.
A reader should distinguish canceling another renewal from seeking a refund for a service already provided or medication already prepared. Ask for the precise deadline and contact method tied to the selected NAD+ plan. A broad recurring-billing provision does not settle the supply duration or prove what every future invoice will contain.
Assess the NAD+ service specifically
The site advertises access to a medical team, including around-the-clock access language. We have not measured response times, and access to messaging is not proof of an immediate clinical reply. Confirm the responsible clinician, pharmacy and route-specific instructions, including who handles questions after a shipment arrives.
The homepage also uses approval language elsewhere in its marketing. That should not be read as FDA approval of a compounded NAD+ preparation; FDA does not approve compounded drugs. The review finding is a documented NAD+ offer with a low headline and unresolved purchase details. A decision needs the exact product, evidence for the intended purpose and a written payment schedule rather than the broader brand presentation.
Useful distinctions
- NAD+ is identified separately from other treatments
- Public recurring-billing terms available
- Clinical-access model described
Limitations to weigh
- Starting price lacks a complete supply and renewal basis
- No verified vial specification
- Endorsements and other-product claims do not establish NAD outcomes
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.